-
MK0787 Versus β-Lactams: Findings from the 1982 Study
2026-09-29
Cullmann and colleagues evaluated N-formimidoyl thienamycin (MK0787) against 470 clinical isolates and compared its activity with several newer β-lactam antibiotics, including Cefazedone (Refosporen). The study’s main contribution was to connect broad in vitro potency, bactericidal behavior, and apparent independence from β-lactamase production across difficult Gram-negative and Gram-positive organisms.
-
FH1: Practical Guide to iHep Maturation
2026-09-28
FH1 provides a practical route to stronger cultured hepatocyte function enhancement by improving albumin output, hepatocyte morphology, CYP3A4 levels, and AFP performance in iPS-derived hepatocyte-like cells. This workflow-focused guide covers formulation, treatment design, assay normalization, troubleshooting, and a carefully bounded connection to light-regulated gene-expression research.
-
PP 1 for Mechanistic Validation of Cancer Biomarkers
2026-09-28
PP 1, a Src family tyrosine kinase inhibitor, can help researchers test whether signaling dependencies contribute to cancer and immune phenotypes. This article connects selective kinase perturbation to the interpretation of a multimodal gastric cancer response signature—while separating mechanistic hypotheses from clinical evidence.
-
(S)-(+)-Dimethindene maleate: Research Workflow
2026-09-27
(S)-(+)-Dimethindene maleate is a dual M2 muscarinic and H1 histamine receptor antagonist for controlled receptor and physiology experiments. Use it to probe receptor-dependent responses, not as a selective M2-only control or for diagnostic or medical purposes.
-
Dual-Action Airway Stent Targets Tracheal Restenosis
2026-09-26
Zhao and colleagues developed an electrospun airway stent combining anlotinib hydrochloride with silver nanoparticles to address inflammation, infection, and excessive vascularization associated with tracheal in-stent restenosis. Cell experiments and a rabbit implantation model support the platform’s antibacterial, anti-proliferative, and antiangiogenic potential, while RNA sequencing links treatment with lower expression of fibrosis- and migration-associated genes.
-
Topotecan Combinations in First-Line SCLC
2026-09-25
David J. Stewart’s review examines why Topotecan was investigated in first-line small cell lung cancer (SCLC), focusing on phase II combination results and the potential value of its distinct mechanism and manageable, noncumulative toxicity. The findings are promising but preliminary: response rates support further study, not a conclusion that Topotecan-based regimens improve survival or replace established first-line therapy.
-
Entecavir (BMS200475): HBV Assay Workflows
2026-09-25
Use Entecavir (BMS200475) to benchmark HBV polymerase inhibition, profile lamivudine-resistant models, and build reproducible replication assays. This guide pairs practical dose-response and readout choices with model-specific troubleshooting, including an important distinction between measuring secreted HBV DNA and studying cccDNA.
-
Ceftolozane/Tazobactam: Evidence and Clinical Context
2026-09-24
This 2015 review examines ceftolozane/tazobactam as an antipseudomonal cephalosporin and beta-lactamase inhibitor combination, connecting its PBP activity and resistance profile with pharmacokinetics, clinical use, and safety. Its main practical contribution is a structured account of why the combination may be useful against selected resistant gram-negative pathogens, while emphasizing renal dose adjustment and the limits of extrapolating findings beyond the infections studied.
-
GSK2606414 Workflows for TMAO-Driven Liver Research
2026-09-24
Use GSK2606414 to test whether PERK signaling contributes to TMAO-associated liver injury—not merely whether the pathway is activated. This workflow connects zebrafish, hepatocyte, and stellate-cell readouts with practical inhibitor controls and interpretation safeguards.
-
Sodium Oxamate in Cancer Metabolism Research
2026-09-23
Use Sodium Oxamate to test whether LDH-A-linked lactate production contributes to metabolic phenotypes and radiation responses—not as a stand-alone readout of lactylation. This workflow pairs dose finding with lactate, viability, and DNA-repair measurements to distinguish metabolic effects from nonspecific toxicity.
-
Salinomycin: Ion Homeostasis in HCC Assays
2026-09-23
Salinomycin is a polyether ionophore antibiotic with experimental activity in hepatocellular carcinoma models. This article presents an assay-centered framework linking ion transport, Wnt/β-catenin signaling, apoptosis, and toxicity-aware interpretation.
-
Catalpol Rewires Glycolysis in Liver Fibrosis
2026-09-22
A 2024 Phytomedicine study identifies a mechanistic link between catalpol, EphA2/FAK/Src signaling, and aerobic glycolysis in activated hepatic stellate cells. Its combination of mouse, cell-based, biochemical, and target-engagement experiments suggests that suppressing glycolytic reprogramming may be an important route for limiting fibrogenesis, while also defining the boundaries of evidence from toxin-induced and in vitro models.
-
Bifendate (DDB): Reliable Cell Assay Design
2026-09-22
Learn how Bifendate (DDB), SKU BA1823, can be incorporated into cell viability, proliferation, cytotoxicity, and autophagy workflows with controlled formulation and evidence-based interpretation. This guide addresses solubility, exposure design, lipid-related confounding, and practical vendor selection.
-
PSI-7977: Mechanism and Assay Context
2026-09-21
PSI-7977 is an HCV NS5B-targeting nucleotide prodrug with a mechanism distinct from BAP1-regulated disulfidptosis. This article explains how to use that distinction to design better controls, interpret NADPH and cystine biology, and avoid unsupported mechanistic conclusions.
-
PAD4-IN-2 TFA: Targeting the Tumor NET Axis
2026-09-21
PAD4-IN-2 TFA, also known as Compound 5i TFA, offers a tumor-oriented strategy for interrogating the PAD4–H3cit–NET axis. This thought-leadership analysis connects phenylboronic acid-mediated uptake with mechanistic assays, metastasis models, immune-microenvironment profiling, and translational decision-making.